Jump to content

Sickle cell disease: Difference between revisions

From Wikipedia, the free encyclopedia
Browse history interactively
← Previous editNext edit →
Content deleted Content added
VisualWikitext
Line 25: Line 25:
Sickle-cell anaemia is the name of a specific form of sickle-cell disease in which there is [[homozygote|homozygosity]] for the [[genetic mutation|mutation]] that causes HbS. Sickle-cell anaemia is also referred to as "HbSS", "SS disease", "haemoglobin S" or permutations thereof. In [[heterozygous]] people, who have only one sickle gene and one normal adult hemoglobin gene, it is referred to as "HbAS" or "sickle cell trait". Other, rarer forms of sickle-cell disease include sickle-[[haemoglobin C]] disease (HbSC), sickle beta-plus-[[thalassaemia]] (HbS/β<sup>+</sup>) and sickle beta-zero-thalassaemia (HbS/β<sup>0</sup>). These other forms of sickle-cell disease are [[compound heterozygous]] states in which the person has only one copy of the mutation that causes HbS and one copy of another abnormal [[haemoglobin]] [[allele]].
Sickle-cell anaemia is the name of a specific form of sickle-cell disease in which there is [[homozygote|homozygosity]] for the [[genetic mutation|mutation]] that causes HbS. Sickle-cell anaemia is also referred to as "HbSS", "SS disease", "haemoglobin S" or permutations thereof. In [[heterozygous]] people, who have only one sickle gene and one normal adult hemoglobin gene, it is referred to as "HbAS" or "sickle cell trait". Other, rarer forms of sickle-cell disease include sickle-[[haemoglobin C]] disease (HbSC), sickle beta-plus-[[thalassaemia]] (HbS/β<sup>+</sup>) and sickle beta-zero-thalassaemia (HbS/β<sup>0</sup>). These other forms of sickle-cell disease are [[compound heterozygous]] states in which the person has only one copy of the mutation that causes HbS and one copy of another abnormal [[haemoglobin]] [[allele]].


The term ''disease'' is applied, because the inherited abnormality causes a pathological condition that can lead to death and severe complications. Not all inherited variants of haemoglobin are detrimental, a concept known as meow[[genetic polymorphism]].
The term ''disease'' is applied, because the inherited abnormality causes a pathological condition that can lead to death and severe complications. Not all inherited variants of haemoglobin are detrimental, a concept known as meow
[[hello]].


==Signs and symptoms==
==Signs and symptoms==

Revision as of 19:08, 18 November 2009

This article is about the disease itself. For the genetic transmission of sickle-cell disease and its carrier state, see sickle cell trait.
Sickle cell disease
SpecialtyHematology Edit this on Wikidata

Sickle-cell disease, or sickle-cell anaemia (or drepanocytosis), is a life-long blood disorder characterized by red blood cells that assume an abnormal, rigid, sickle shape. Sickling decreases the cells' flexibility and results in a risk of various complications. The sickling occurs because of a mutation in the hemoglobin gene. Life expectancy is shortened, with studies reporting an average life expectancy of 42 and 48 years for males and females, respectively.[1]

Sickle-cell disease, usually presenting in childhood, occurs more commonly in people (or their descendants) from parts of tropical and sub-tropical regions where malaria is or was common. One-third of all indigenous inhabitants of Sub-Saharan Africa carry the gene[2], because in areas where malaria is common, there is a survival value in carrying only a single sickle-cell gene (sickle cell trait).[3] Those with only one of the two alleles of the sickle-cell disease are more resistant to malaria, since the infestation of the malaria plasmodium is halted by the sickling of the cells which it infests.

The prevalence of the disease in the United States is approximately 1 in 5,000, mostly affecting Americans of Sub-Saharan African descent, according to the National Institutes of Health.[4] In the United States, about 1 in 500 black births have sickle-cell anemia.

Classification

Sickle-cell anaemia is the name of a specific form of sickle-cell disease in which there is homozygosity for the mutation that causes HbS. Sickle-cell anaemia is also referred to as "HbSS", "SS disease", "haemoglobin S" or permutations thereof. In heterozygous people, who have only one sickle gene and one normal adult hemoglobin gene, it is referred to as "HbAS" or "sickle cell trait". Other, rarer forms of sickle-cell disease include sickle-haemoglobin C disease (HbSC), sickle beta-plus-thalassaemia (HbS/β+) and sickle beta-zero-thalassaemia (HbS/β0). These other forms of sickle-cell disease are compound heterozygous states in which the person has only one copy of the mutation that causes HbS and one copy of another abnormal haemoglobin allele.

The term disease is applied, because the inherited abnormality causes a pathological condition that can lead to death and severe complications. Not all inherited variants of haemoglobin are detrimental, a concept known as meow


hello.

Signs and symptoms

Sickle-cell disease may lead to various acute and chronic complications, several of which are potentially lethal.

Vaso-occlusive crisis

The vaso-occlusive crisis is caused by sickle-shaped red blood cells that obstruct capillaries and restrict blood flow to an organ, resulting in ischemia, pain, and often organ damage. The frequency, severity, and duration of these crises vary considerably. Painful crises are treated with hydration and analgesics; pain management requires opioid administration at regular intervals until the crisis has settled. For milder crises, a subgroup of patients manage on NSAIDs (such as diclofenac or naproxen). For more severe crises, most patients require inpatient management for intravenous opioids; patient-controlled analgesia (PCA) devices are commonly used in this setting. Diphenhydramine is sometimes effective for the itching associated with the opioid use. Incentive spirometry, a technique to encourage deep breathing to minimise the development of atelectasis, is recommended.

Because of its narrow vessels and function in clearing defective red blood cells, the spleen is frequently affected. It is usually infarcted before the end of childhood in individuals suffering from sickle-cell anaemia. This autosplenectomy increases the risk of infection from encapsulated organisms;[5][6] preventive antibiotics and vaccinations are recommended for those with such asplenia.

One of the earliest clinical manifestations is dactylitis, presenting as early as six months of age, and may occur in children with sickle trait.[7] The crisis can last up to a month.[8] Another recognised type of sickle crisis is the acute chest syndrome, a condition characterised by fever, chest pain, difficulty breathing, and pulmonary infiltrate on a chest X-ray. Given that pneumonia and sickling in the lung can both produce these symptoms, the patient is treated for both conditions.[citation needed] It can be triggered by painful crisis, respiratory infection, bone-marrow embolisation, or possibly by atelectasis, opiate administration, or surgery.

Most episodes of sickle cell crises last between five and seven days.[9]

Other sickle-cell crises

  • Aplastic crises are acute worsenings of the patient's baseline anaemia, producing pallor, tachycardia, and fatigue. This crisis is triggered by parvovirus B19, which directly affects erythropoiesis (production of red blood cells). Parvovirus infection nearly completely prevents red blood cell production for two to three days. In normal individuals, this is of little consequence, but the shortened red cell life of sickle-cell patients results in an abrupt, life-threatening situation. Reticulocyte counts drop dramatically during the disease, and the rapid turnover of red cells leads to the drop in hemoglobin. Most patients can be managed supportively; some need blood transfusion.
  • Splenic sequestration crises are acute, painful enlargements of the spleen. The abdomen becomes bloated and very hard. Management is supportive, sometimes with blood transfusion.
  • Hemolytic crises are acute accelerated drops in hemoglobin level. The red blood cells break down at a faster rate. This is particularly common in patients with co-existent G6PD deficiency. Management is supportive, sometimes with blood transfusions.

Complications

Sickle-cell anaemia can lead to various complications, including:

  • Overwhelming post-(auto)splenectomy infection (OPSI), which is due to functional asplenia, caused by encapsulated organisms such as Streptococcus pneumoniae and Haemophilus influenzae. Daily penicillin prophylaxis is the most commonly used treatment during childhood, with some haematologists continuing treatment indefinitely. Patients benefit today from routine vaccination for H. influenzae, S. pneumoniae, and Neisseria meningitidis.
  • Stroke, which can result from a progressive vascular narrowing of blood vessels, preventing oxygen from reaching the brain. Cerebral infarction occurs in children, and cerebral hemorrhage in adults.
  • Cholelithiasis (gallstones) and cholecystitis, which may result from excessive bilirubin production and precipitation due to prolonged haemolysis.
  • Jaundice, yellowing of the skin, may occur due to the inability of the liver to effectively remove bilirubin from the filtering of damaged red blood cells out of the blood supply as well as blocks in the organ's blood supply.[10][11]
  • Avascular necrosis (aseptic bone necrosis) of the hip and other major joints, which may occur as a result of ischemia.
  • Decreased immune reactions due to hyposplenism (malfunctioning of the spleen).
  • Priapism and infarction of the penis.
  • Osteomyelitis (bacterial bone infection), which is most frequently caused by Salmonella in individuals with sickle-cell disease, whereas Staphylococcus is the most common causative organism in the general population.
  • Opioid tolerance, which can occur as a normal, physiologic response to the therapeutic use of opiates. Addiction to opiates occurs no more commonly among individuals with sickle-cell disease than among other individuals treated with opiates for other reasons.
  • Acute papillary necrosis in the kidneys.
  • Leg ulcers.
  • In eyes, background retinopathy, proliferative retinopathy, vitreous haemorrhages and retinal detachments, resulting in blindness. Regular annual eye checks are recommended.
  • During pregnancy, intrauterine growth retardation, spontaneous abortion, and pre-eclampsia.
  • Chronic pain: Even in the absence of acute vaso-occlusive pain, many patients have chronic pain that is not reported[12].
  • Pulmonary hypertension (increased pressure on the pulmonary artery), leading to strain on the right ventricle and a risk of heart failure; typical symptoms are shortness of breath, decreased exercise tolerance and episodes of syncope[13].
  • Chronic renal failure—manifests itself with hypertension (high blood pressure), proteinuria (protein loss in the urine), hematuria (loss of red blood cells in urine) and worsened anaemia. If it progresses to end-stage renal failure, it carries a poor prognosis.[14]

Heterozygotes

The heterozygous form (sickle cell trait) is almost always asymptomatic, and the only usual significant manifestation is the renal concentrating defect presenting with isosthenuria.

Diagnosis

In HbSS, the full blood count reveals haemoglobin levels in the range of 6–8 g/dL with a high reticulocyte count (as the bone marrow compensates for the destruction of sickle cells by producing more red blood cells). In other forms of sickle-cell disease, Hb levels tend to be higher. A blood film may show features of hyposplenism (target cells and Howell-Jolly bodies).

Sickling of the red blood cells, on a blood film, can be induced by the addition of sodium metabisulfite. The presence of sickle haemoglobin can also be demonstrated with the "sickle solubility test". A mixture of haemoglobin S (Hb S) in a reducing solution (such as sodium dithionite) gives a turbid appearance, whereas normal Hb gives a clear solution.

Abnormal haemoglobin forms can be detected on haemoglobin electrophoresis, a form of gel electrophoresis on which the various types of haemoglobin move at varying speeds. Sickle-cell haemoglobin (HgbS) and haemoglobin C with sickling (HgbSC)—the two most common forms—can be identified from there. The diagnosis can be confirmed with high-performance liquid chromatography (HPLC). Genetic testing is rarely performed, as other investigations are highly specific for HbS and HbC.[15]

An acute sickle-cell crisis is often precipitated by infection. Therefore, a urinalysis to detect an occult urinary tract infection, and chest X-ray to look for occult pneumonia should be routinely performed.[16]

Pathophysiology

Sickle-cell anaemia is caused by a point mutation in the β-globin chain of haemoglobin, causing the hydrophilic amino acid glutamic acid to be replaced with the hydrophobic amino acid valine at the sixth position. The β-globin gene is found on the short arm of chromosome 11. The association of two wild-type α-globin subunits with two mutant β-globin subunits forms haemoglobin S (HbS). Under low-oxygen conditions (being at high altitude, for example), the absence of a polar amino acid at position six of the β-globin chain promotes the non-covalent polymerisation (aggregation) of haemoglobin, which distorts red blood cells into a sickle shape and decreases their elasticity.

The loss of red blood cell elasticity is central to the pathophysiology of sickle-cell disease. Normal red blood cells are quite elastic, which allows the cells to deform to pass through capillaries. In sickle-cell disease, low-oxygen tension promotes red blood cell sickling and repeated episodes of sickling damage the cell membrane and decrease the cell's elasticity. These cells fail to return to normal shape when normal oxygen tension is restored. As a consequence, these rigid blood cells are unable to deform as they pass through narrow capillaries, leading to vessel occlusion and ischaemia.

The actual anemia of the illness is caused by hemolysis, the destruction of the red cells inside the spleen, because of their misshape. Although the bone marrow attempts to compensate by creating new red cells, it does not match the rate of destruction.[17] Healthy red blood cells typically live 90-120 days, but sickle cells only survive 10–20 days.[18]

Genetics

File:Sickle cell haemoglobin.png
A single amino acid change causes haemoglobin proteins to form fibers.

Sickle-cell gene mutation probably arose spontaneously in different geographic areas, as suggested by restriction endonuclease analysis. These variants are known as Cameroon, Senegal, Benin, Bantu and Saudi-Asian. Their clinical importance springs from the fact that some of them are associated with higher HbF levels, e.g., Senegal and Saudi-Asian variants, and tend to have milder disease.[19]

In people heterozygous for HgbS (carriers of sickling haemoglobin), the polymerisation problems are minor, because the normal allele is able to produce over 50% of the haemoglobin. In people homozygous for HgbS, the presence of long-chain polymers of HbS distort the shape of the red blood cell from a smooth donut-like shape to ragged and full of spikes, making it fragile and susceptible to breaking within capillaries. Carriers have symptoms only if they are deprived of oxygen (for example, while climbing a mountain) or while severely dehydrated. Under normal circumstances, these painful crises occur 0.8 times per year per patient.[citation needed] The sickle-cell disease occurs when the seventh amino acid (if we count the initial methionine), glutamic acid, is replaced by valine to change its structure and function.

Distribution of the sickle-cell trait shown in pink and purple
Historical distribution of malaria (no longer endemic in Europe) shown in green
Modern distribution of malaria

The gene defect is a known mutation of a single nucleotide (see single nucleotide polymorphism - SNP) (A to T) of the β-globin gene, which results in glutamate being substituted by valine at position 6. Haemoglobin S with this mutation are referred to as HbS, as opposed to the normal adult HbA. The genetic disorder is due to the mutation of a single nucleotide, from a GAG to GTG codon mutation. This is normally a benign mutation, causing no apparent effects on the secondary, tertiary, or quaternary structure of haemoglobin in conditions of normal oxygen concentration. What it does allow for, under conditions of low oxygen concentration, is the polymerization of the HbS itself. The deoxy form of haemoglobin exposes a hydrophobic patch on the protein between the E and F helices. The hydrophobic residues of the valine at position 6 of the beta chain in haemoglobin are able to associate with the hydrophobic patch, causing haemoglobin S molecules to aggregate and form fibrous precipitates.

The allele responsible for sickle-cell anaemia is autosomal incomplete dominant and can be found on the short arm of chromosome 11. A person that receives the defective gene from both father and mother develops the disease; a person that receives one defective and one healthy allele remains healthy, but can pass on the disease and is known as a carrier. If two parents who are carriers have a child, there is a 1-in-4 chance of their child's developing the disease and a 1-in-2 chance of their child's being just a carrier. Since the gene is incompletely recessive, carriers can produce a few sickled red blood cells, not enough to cause symptoms, but enough to give resistance to malaria. Because of this, heterozygotes have a higher fitness than either of the homozygotes. This is known as heterozygote advantage.

Due to the adaptive advantage of the heterozygote, the disease is still prevalent, especially among people with recent ancestry in malaria-stricken areas, such as Africa, the Mediterranean, India and the Middle East.[20] Malaria was historically endemic to southern Europe, but it was declared eradicated in the mid-20th century, with the exception of rare sporadic cases.[21][22]

The Price equation is a simplified mathematical model of the genetic evolution of sickle-cell anaemia.

The malaria parasite has a complex life cycle and spends part of it in red blood cells. In a carrier, the presence of the malaria parasite causes the red blood cells with defective haemoglobin to rupture prematurely, making the plasmodium unable to reproduce. Further, the polymerization of Hb affects the ability of the parasite to digest Hb in the first place. Therefore, in areas where malaria is a problem, people's chances of survival actually increase if they carry sickle-cell trait (selection for the heterozygote).

In the USA, where there is no endemic malaria, the prevalence of sickle-cell anaemia among blacks is lower (about 0.25%) than in West Africa (about 4.0%) and is falling. Without endemic malaria from Africa, the sickle cell mutation is purely disadvantageous and will tend to be selected out of the affected population. Another factor limiting the spread of sickle-cell genes in North America is the absence of cultural proclivities to polygamy. [23]

Sickle-cell disease is inherited in the autosomal recessive pattern.

Inheritance

  • Sickle-cell conditions are inherited from parents in much the same way as blood type, hair color and texture, eye color, and other physical traits.
  • The types of haemoglobin a person makes in the red blood cells depend on what haemoglobin genes are inherited from his parents.
  1. If one parent has sickle-cell anaemia (SS) and the other has sickle-cell trait (AS), there is a 50% chance of a child's having sickle-cell disease (SS) and a 50% chance of a child's having sickle-cell trait (AS).
  2. When both parents have sickle-cell trait (AS), a child has a 25% chance (1 of 4) of sickle-cell disease (SS), as shown in the diagram.

Treatment

Cyanate

Dietary cyanate, from foods containing cyanide derivatives, has been used as a treatment for sickle- cell anemia.[24] In the laboratory, cyanate and thiocyanate irreversibly inhibit sickling of red blood cells drawn from sickle cell anemia patients.[25] However, the cyanate would have to be administered to the patient for a lifetime, as each new red blood cell created must be prevented from sickling at the time of creation. Cyanate also would be expelled via the urea of a patient every cycle of treatment. Also see nicosan.

Painful (vaso-occlusive) crisis

Most people with sickle-cell disease have intensely painful episodes called vaso-occlusive crises. The frequency, severity, and duration of these crises, however, vary tremendously. Painful crises are treated symptomatically with analgesics; pain management requires opioid administration at regular intervals until the crisis has settled. For milder crises, a subgroup of patients manage on NSAIDs (such as diclofenac or naproxen). For more severe crises, most patients require inpatient management for intravenous opioids; patient-controlled analgesia (PCA) devices are commonly used in this setting. Diphenhydramine is also an effective agent that is frequently prescribed by doctors in order to help control any itching associated with the use of opioids.

Folic acid and penicillin

Children born with sickle-cell disease will undergo close observation by the pediatrician and will require management by a hematologist to assure they remain healthy. These patients will take a 1 mg dose of folic acid daily for life. From birth to five years of age, they will also have to take penicillin daily due to the immature immune system that makes them more prone to early childhood illnesses.

Acute chest crisis

Management is similar to vaso-occlusive crisis, with the addition of antibiotics (usually a quinolone or macrolide, since wall-deficient ["atypical"] bacteria are thought to contribute to the syndrome),[26] oxygen supplementation for hypoxia, and close observation. Should the pulmonary infiltrate worsen or the oxygen requirements increase, simple blood transfusion or exchange transfusion is indicated. The latter involves the exchange of a significant portion of the patients red cell mass for normal red cells, which decreases the percent of haemoglobin S in the patient's blood.

Hydroxyurea

The first approved drug for the causative treatment of sickle-cell anaemia, hydroxyurea, was shown to decrease the number and severity of attacks in a study in 1995 (Charache et al.)[27] and shown to possibly increase survival time in a study in 2003 (Steinberg et al.).[28] This is achieved, in part, by reactivating fetal haemoglobin production in place of the haemoglobin S that causes sickle-cell anaemia. Hydroxyurea had previously been used as a chemotherapy agent, and there is some concern that long-term use may be harmful, but this risk has been shown to be either absent or very small and it is likely that the benefits outweigh the risks.[29]

Bone marrow transplants

Bone marrow transplants have proven to be effective in children.[30]

Future treatments

Various approaches are being sought for preventing sickling episodes as well as for the complications of sickle-cell disease. Other ways to modify hemoglobin switching are being investigated, including the use of phytochemicals such as nicosan. Gene therapy is under investigation.

Another treatment being investigated is Senicapoc.[31]

Situation of carriers

People who are known carriers of the disease often undergo genetic counseling before they have a child. A test to see if an unborn child has the disease takes either a blood sample from the fetus or a sample of amniotic fluid. Since taking a blood sample from a fetus has greater risks, the latter test is usually used.

After the mutation responsible for this disease was discovered in 1979, the U.S. Air Force required black applicants to test for the mutation. It dismissed 143 applicants because they were carriers, even though none of them had the condition. It eventually withdrew the requirement, but only after a trainee filed a lawsuit.[32]

History

This collection of clinical findings was unknown until the explanation of the sickle cells in 1904 by the Chicago cardiologist and professor of medicine James B. Herrick (1861-1954), whose intern Ernest Edward Irons (1877-1959) found "peculiar elongated and sickle-shaped" cells in the blood of Walter Clement Noel, a 20-year-old first-year dental student from Grenada, after Noel was admitted to the Chicago Presbyterian Hospital in December 1904 suffering from anaemia. [33]

Noel was readmitted several times over the next three years for "muscular rheumatism" and "bilious attacks". Noel completed his studies and returned to the capital of Grenada (St. George's) to practice dentistry. He died of pneumonia in 1916 and is buried in the Catholic cemetery at Sauteurs in the north of Grenada.[34]

The disease was named "sickle-cell anaemia" by Vernon Mason in 1922. However, some elements of the disease had been recognized earlier: A paper in the Southern Journal of Medical Pharmacology in 1846 described the absence of a spleen in the autopsy of a runaway slave. The African medical literature reported this condition in the 1870s, when it was known locally as ogbanjes ("children who come and go") because of the very high infant mortality rate caused by this condition. A history of the condition tracked reports back to 1670 in one Ghanaian family.[35] Also, the practice of using tar soap to cover blemishes caused by sickle-cell sores was prevalent in the black community.[citation needed]

Linus Pauling and colleagues were the first, in 1949, to demonstrate that sickle-cell disease occurs as a result of an abnormality in the haemoglobin molecule. This was the first time a genetic disease was linked to a mutation of a specific protein, a milestone in the history of molecular biology, and it was published in their paper "Sickle Cell Anemia, a Molecular Disease".

The origin of the mutation that led to the sickle-cell gene was initially thought to be in the Arabian peninsula, spreading to Asia and Africa. It is now known, from evaluation of chromosome structures, that there have been at least four independent mutational events, three in Africa and a fourth in either Saudi Arabia or central India. These independent events occurred between 3,000 and 6,000 generations ago, approximately 70-150,000 years.[36]

See also

References

  1. ^ Platt OS, Brambilla DJ, Rosse WF; et al. (1994). "Mortality in sickle cell disease. Life expectancy and risk factors for early death". N. Engl. J. Med. 330 (23): 1639–44. doi:10.1056/NEJM199406093302303. ISSN 0028-4793. PMID 7993409. {{cite journal}}: Explicit use of et al. in: |author= (help); Unknown parameter |month= ignored (help)CS1 maint: multiple names: authors list (link)
  2. ^ Sicklecell.md
  3. ^ Sicklecell.md FAQ: "Why is Sickle Cell Anaemia only found in Black people?
  4. ^ http://www.nhlbi.nih.gov/health/dci/Diseases/Sca/SCA_Summary.html
  5. ^ Pearson H (1977). "Sickle cell anaemia and severe infections due to encapsulated bacteria" (Free full text). J Infect Dis. 136 Suppl: S25–30. ISSN 0022-1899. PMID 330779. {{cite journal}}: Unknown parameter |month= ignored (help)
  6. ^ Wong W, Powars D, Chan L, Hiti A, Johnson C, Overturf G (1992). "Polysaccharide encapsulated bacterial infection in sickle cell anaemia: a thirty year epidemiologic experience" (Free full text). Am J Hematol. 39 (3): 176–82. doi:10.1002/ajh.2830390305. ISSN 0361-8609. PMID 1546714. {{cite journal}}: Unknown parameter |month= ignored (help)CS1 maint: multiple names: authors list (link)
  7. ^ Jadavji T, Prober CG (1985). "Dactylitis in a child with sickle cell trait". Can Med Assoc J. 132 (7): 814–5. ISSN 0008-4409. PMC 1345873. PMID 3978504. {{cite journal}}: Unknown parameter |month= ignored (help)
  8. ^ http://www.ejbjs.org/cgi/content/abstract/58/8/1161
  9. ^ "BestBets: How long should an average sickle cell crisis last?".
  10. ^ "Sickle cell anemia". Mayo Clinic. 2009-04-01. Retrieved 2009-05-02.
  11. ^ Bandyopadhyay R, Bandyopadhyay SK, Dutta A (2008). "Sickle cell hepatopathy". Indian J Pathol Microbiol. 51 (2): 284–5. doi:10.4103/0377-4929.41698. ISSN 0377-4929. PMID 18603711. {{cite journal}}: Unknown parameter |month= ignored (help)CS1 maint: multiple names: authors list (link) CS1 maint: unflagged free DOI (link)
  12. ^ Smith WR, Penberthy LT, Bovbjerg VE; et al. (2008). "Daily assessment of pain in adults with sickle cell disease". Ann. Intern. Med. 148 (2): 94–101. ISSN 0003-4819. PMID 18195334. {{cite journal}}: Explicit use of et al. in: |author= (help); Unknown parameter |month= ignored (help)CS1 maint: multiple names: authors list (link)
  13. ^ Gladwin MT, Sachdev V, Jison ML; et al. (2004). "Pulmonary hypertension as a risk factor for death in patients with sickle cell disease". N. Engl. J. Med. 350 (9): 886–95. doi:10.1056/NEJMoa035477. ISSN 0028-4793. PMID 14985486. {{cite journal}}: Explicit use of et al. in: |author= (help); Unknown parameter |month= ignored (help)CS1 maint: multiple names: authors list (link)
  14. ^ Powars DR, Elliott-Mills DD, Chan L; et al. (1991). "Chronic renal failure in sickle cell disease: risk factors, clinical course, and mortality". Ann. Intern. Med. 115 (8): 614–20. ISSN 0003-4819. PMID 1892333. {{cite journal}}: Explicit use of et al. in: |author= (help); Unknown parameter |month= ignored (help)CS1 maint: multiple names: authors list (link)
  15. ^ Clarke GM, Higgins TN (2000). "Laboratory investigation of hemoglobinopathies and thalassemias: review and update". Clin. Chem. 46 (8 Pt 2): 1284–90. ISSN 0009-9147. PMID 10926923. {{cite journal}}: Unknown parameter |month= ignored (help)
  16. ^ "BestBets: Does routine urinalysis and chest radiography detect occult bacterial infection in sickle cell patients presenting to the accident and emergency department with painful crisis?".
  17. ^ http://sickle.bwh.harvard.edu/scd_background.html
  18. ^ http://emedicine.medscape.com/article/778971-overview
  19. ^ Green NS, Fabry ME, Kaptue-Noche L, Nagel RL (1993). "Senegal haplotype is associated with higher HbF than Benin and Cameroon haplotypes in African children with sickle cell anemia" (Free full text). Am. J. Hematol. 44 (2): 145–6. doi:10.1002/ajh.2830440214. ISSN 0361-8609. PMID 7505527. {{cite journal}}: Unknown parameter |month= ignored (help)CS1 maint: multiple names: authors list (link)
  20. ^ Kwiatkowski DP (2005). "How malaria has affected the human genome and what human genetics can teach us about malaria". Am. J. Hum. Genet. 77 (2): 171–92. doi:10.1086/432519. ISSN 0002-9297. PMID 16001361. {{cite journal}}: Unknown parameter |month= ignored (help) PMC 1224522
  21. ^ http://www.cdc.gov/ncidod/EID/vol7no6/romi.htm
  22. ^ http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=1808464
  23. ^ http://journals.cambridge.org/action/displayAbstract?aid=1361276
  24. ^ http://www.clarafelixclinic.org/assets/further_info/cyanate_houston.pdf
  25. ^ http://www.clarafelixclinic.org/assets/further_info/thiocyanate_agbai.pdf
  26. ^ Aldrich TK, Nagel RL. (1998). "Pulmonary Complications of Sickle Cell Disease.". In C et al., editors (ed.). Pulmonary and Critical Care Medicine (6th ed.). St. Louis: Mosby. pp. pp.1–10. ISBN 0-81511-371-4. {{cite book}}: |editor= has generic name (help); |pages= has extra text (help)
  27. ^ Charache S, Terrin ML, Moore RD; et al. (1995). "Effect of hydroxyurea on the frequency of painful crises in sickle cell anemia. Investigators of the Multicenter Study of Hydroxyurea in Sickle Cell Anemia". N. Engl. J. Med. 332 (20): 1317–22. doi:10.1056/NEJM199505183322001. ISSN 0028-4793. PMID 7715639. {{cite journal}}: Explicit use of et al. in: |author= (help); Unknown parameter |month= ignored (help)CS1 maint: multiple names: authors list (link)
  28. ^ Steinberg MH, Barton F, Castro O; et al. (2003). "Effect of hydroxyurea on mortality and morbidity in adult sickle cell anemia: risks and benefits up to 9 years of treatment". JAMA. 289 (13): 1645–51. doi:10.1001/jama.289.13.1645. ISSN 0098-7484. PMID 12672732. {{cite journal}}: Explicit use of et al. in: |author= (help); Unknown parameter |month= ignored (help)CS1 maint: multiple names: authors list (link)
  29. ^ Platt OS (2008). "Hydroxyurea for the treatment of sickle cell anemia". N. Engl. J. Med. 358 (13): 1362–9. doi:10.1056/NEJMct0708272. ISSN 0028-4793. PMID 18367739. {{cite journal}}: Unknown parameter |month= ignored (help)
  30. ^ Walters MC, Patience M, Leisenring W; et al. (1996). "Bone marrow transplantation for sickle cell disease". N. Engl. J. Med. 335 (6): 369–76. doi:10.1056/NEJM199608083350601. ISSN 0028-4793. PMID 8663884. {{cite journal}}: Explicit use of et al. in: |author= (help); Unknown parameter |month= ignored (help)CS1 maint: multiple names: authors list (link)
  31. ^ Ataga KI, Stocker J (2009). "Senicapoc (ICA-17043): a potential therapy for the prevention and treatment of hemolysis-associated complications in sickle cell anemia". Expert Opin Investig Drugs. 18 (2): 231–9. doi:10.1517/13543780802708011. ISSN 1354-3784. PMID 19236269. {{cite journal}}: Unknown parameter |month= ignored (help)
  32. ^ Anonymous (4 January 1981). "Air force academy sued over sickle cell policy". New York Times. Retrieved 21 December 2008.
  33. ^ Herrick, J.B. (1910). "Peculiar elongated and sickle-shaped red blood corpuscles in a case of severe anemia". Archives of Internal Medicine. 6: 517–521.
  34. ^ Savitt TL, Goldberg MF (1989). "Herrick's 1910 case report of sickle cell anemia. The rest of the story" (Free full text). JAMA. 261 (2): 266–71. doi:10.1001/jama.261.2.266. ISSN 0098-7484. PMID 2642320. {{cite journal}}: Unknown parameter |month= ignored (help)
  35. ^ Konotey-Ahulu FID. Effect of environment on sickle cell disease in West Africa: epidemiologic and clinical considerations. In: Sickle Cell Disease, Diagnosis, Management, Education and Research. Abramson H, Bertles JF, Wethers DL, eds. CV Mosby Co, St. Louis. 1973; 20; cited in Desai, D. V. (2004). "Sickle Cell Disease: History And Origin". The Internet Journal of Haematology. 1 (2). ISSN 1540-2649. {{cite journal}}: Unknown parameter |coauthors= ignored (|author= suggested) (help)
  36. ^ Desai, D. V. (2004). "Sickle Cell Disease: History And Origin". The Internet Journal of Haematology. 1 (2). ISSN 1540-2649. {{cite journal}}: Unknown parameter |coauthors= ignored (|author= suggested) (help)

{{Diseases of RBCs and megakaryocytes}} may refer to:

{{Template disambiguation}} should never be transcluded in the main namespace.

Retrieved from "https://en.wikipedia.org/enwiki/w/index.php?title=Sickle_cell_disease&oldid=326585595"